Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Wednesday 24 June 2026 2:08 pm  |  Updated:  Monday 29 June 2026 10:04 am

StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide

By: Business Wire

Add as a preferred source on Google

StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, today announced the global launch of the CytoPath Disc, an innovative cell block preparation technology designed to standardize and simplify cell block preparation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624368623/en/

Developed as an alternative to traditional cell block methods, which convert concentrated cells suspended in fluid into a paraffin-embedded format for slide-based evaluation, the patent‑pending CytoPath Disc offers a more streamlined and efficient approach. The CytoPath Disc absorbs concentrated cells within a simple, sponge-like matrix, which is then processed, embedded, stained, and sectioned using standard histology workflows.

Traditional cell block preparation methods often present challenges in achieving consistent results due to complex procedures, as well as the need for additional equipment or reagents. The CytoPath Discs enable labs to standardize cell block preparation, delivering reliable, reproducible samples that are proven to support accurate diagnoses in downstream IHC and molecular applications.

Designed and developed in StatLab’s Martinengo site by Diapath, the launch highlights the strength of the organization’s integrated global Research and Development capabilities. The CytoPath Disc complements StatLab’s existing portfolio of cytology essentials, including fixatives, stains, and slides, supporting effective pre-analytical sample preparation.

“Laboratories are under increasing pressure to deliver accurate, reproducible results efficiently,” said Lance Mikus, Vice President of Product Management and Marketing at StatLab. “With CytoPath Disc, we are providing a practical solution that enhances consistency while simplifying the cell block preparation process. This innovation is another step forward in our mission to empower our customers to provide the best possible patient care, and is a great example of the power that comes from the collaboration between our global R&D sites.”

CytoPath Discs are available for order today through all StatLab brands and authorized partners. For more information, visit StatLab.com/CytoPath-Discs.

About StatLab Medical Products

StatLab Medical Products has been dedicated to helping anatomic pathology laboratories provide the best possible patient care for 50 years. We offer a complete portfolio of self-manufactured pathology equipment and consumables from nine manufacturing sites in the United States, United Kingdom, and Europe. Our global operational footprint powered by over 850 mission-driven colleagues delivers a dependable and resilient supply chain of high-quality products and solutions, and a customer-centric approach inspires us to deliver reliability, innovation, and quality in every interaction. Learn more at StatLab.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260624368623/en/

Contact

Media Contact:
Jessica Baer
VP, Global Marketing, StatLab
[email protected]
630-346-1659

TweetText

The CytoPath Discs enable labs to standardize cell block preparation, delivering reliable, reproducible samples that are proven to support accurate diagnoses in downstream IHC and molecular applications.

🎥 The CytoPath Disc from StatLab offers a new, user-friendly, standardized method for cell block creation.
Company Logo

VIDEO: The CytoPath Disc from StatLab offers a new, user-friendly, standardized method for cell block creation.

Company Logo


Read more

Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Businesswire

Categories

  • Photo/Multimedia
  • Product/Service

Trending Articles

  • Top Burnham adviser calls for capital gains and inheritance tax hikes

  • A meeting with the breakfast king of Mayfair

  • Clarkson’s Farm and why businesses must stop blaming the weather

  • As it happened: Supreme Court blocks Trump sacking; Andy Burnham vows ‘greater public control’; Comcast spin-off

  • BT tops FTSE 100 after finding new home for international business with Verizon joint venture

More from City PM

  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire
  • morph Launches the World’s First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World Applications

    Business Wire
  • Dr Mom Hand Unveils Phyto-Resonance®

    Business Wire
  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • H55 Delivers Certification-Grade Propulsion Battery Modules to Pratt & Whitney Canada, Supporting Demonstration of Hybrid-Electric Aircraft Technology

    Business Wire
  • Legado and Amiqus Partner to Streamline Regulated Onboarding in UK Financial Services Sector

    Business Wire
  • Xsolla to Sponsor First Playable Florence 2026, Equipping Indie PC Developers With Publisher Pitch Strategies and a Scalable Alternative to Paid Acquisition

    Business Wire
  • Lightspeed Successfully Supports New Intraday Margin Trading Framework

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy